FDA approves label expansion of AbbVie hepatitis C therapy
The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric …
Post
-
-
BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition
BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy …
-
Wes Streeting: £29bn NHS boost ‘substantial’ but reform still needed
A £29bn investment into the National Health System (NHS) is ‘substantial’, but reform of the system is essential to ‘fix …
-
Vaccine sceptics among new members hired by RFK Jr for CDC’s vaccine panel
US Health Secretary Robert F Kennedy (RFK) Jr has appointed eight new members to the vaccine advisory panel at the …
-
Vutrisiran marks first silencer approved for ATTR-CM
Transthyretin amyloidosis (ATTR) is a protein conformational disorder caused by the build-up of transthyretin, the protein carrying thyroxine and retinol …
-
Enterome to advance EO2463 immunotherapy with $19m funding
Enterome has secured $19m in new private funding to progress its EO2463 OncoMimics immunotherapy, targeting indolent non-Hodgkin's lymphoma (iNHL). The funding …
-
Customs simplified: the need to streamline pharma shipments
Pharmaceutical supply chains continue to be disrupted by a range of geopolitical factors, including global conflict, economic uncertainty, and especially …
-
Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m …
-
FDA approves Capsida’s CAP-003 gene therapy for Parkinson’s
The US Food and Drug Administration (FDA) has approved Capsida Biotherapeutics' investigational new drug (IND) application for CAP-003 to treat …
-
SpliceBio secures $135m for gene therapy development
SpliceBio has closed a Series B financing round, raising $135m for the clinical development of SB-007, its gene therapy candidate …
-
Gilead hit with FDA clinical hold for batch of HIV trials
The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV …
-
NHS to receive £29bn funding boost
The UK’s National Health Service (NHS) is receiving a £29bn ($39.1bn) funding boost, reflecting a 3% annual rise on current …
-
Echosens and Boehringer expand partnership for MASH diagnosis
Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in metabolic dysfunction-associated steatohepatitis (MASH) diagnosis and care. The …
-
Trump’s push to onshore pharma manufacturing clouded by ‘lack of clarity’
A degree of uncertainty reigns over the implementation of regulations imposed by US President Donald Trump that aim to bolster …
-
Antares Therapeutics gains $177m for cancer medicines development
Antares Therapeutics has secured $177m in a Series A financing round for the development of precision medicines to treat cancer …
